SU5416 Semaxanib Cas 204005-46-9 Quinolone Derivative
SU5416 Semaxanib Cas 204005-46-9 Quinolone Derivative
+ AII PRODUCTS
- Prostaglandins - Custom Synthesis - PARP Inhibitors - PI3K Inhibitors - FAK Inhibitors - AKT Inhibitors - C-Kit Inhibitors - VEGFR Inhibitors - c-Met Inhibitors - CDK Inhibitors - CYP17 Inhibitors - DNA/RNA Inhibitors - mTOR Inhibitors - SRC Inhibitors - Others
Product
|
Size |
Price |
Stock |
Quantity |
|---|---|---|---|
|
Get Quotation Now Add to Cart Bulk Inquiry |
|||
AddThis Sharing Buttons
Share to FacebookFacebookShare to TwitterTwitterShare to PrintPrintShare to EmailEmailShare to PinterestPinterestShare to GmailGmailShare to LinkedInLinkedInShare to Email AppEmail AppShare to TumblrTumblrShare to MoreAddThis
Shipping and handling fee USD40, Free delivery is qualified when the total value of your order exceeds USD500.If the item is temporarily out of stock. Please email to order@pharm-intermediates.com,we will inform you when we have it in stock.
Chemical Information
|
Product name:SU5416 Semaxanib |
Purity:98% min |
|
CAS NO:204005-46-9 |
Solubility:DMSO22.5 mg/mL (94.43 mM); H2O< 0.1 mg/mL |
|
Molecular Formula:C15H14N2O |
Package:Package according to customer requirements |
|
Molecular Weight:238.284 |
Storage:Store at -20℃ |
Quality control
Remarks
Semaxanib, also known as SU5416, is a quinolone derivative with potential antineoplastic activity. Semaxanib reversibly inhibits ATP binding to the tyrosine kinase domain of vascular endothelial growth factor receptor 2 (VEGFR2), which may inhibit VEGF-stimulated endothelial cell migration and proliferation and reduce the tumor microvasculature. This agent also inhibits the phosphorylation of the stem cell factor receptor tyrosine kinase c-kit, often expressed in acute myelogenous leukemia cells.
Related Prodcuts:
LY2874455; ZM-306416; ZM323881; Tyrphostin A9; Orantinib; Brivanib; Foretinib; SU5402;SAR131675; Lucitanib; Apatinib; SKLB610; Altiratinib; SGI-7079; AZD2932
References
[1].Fong TA, et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res, 1999, 59(1), 99-106.
[2].Vajkoczy P, et al. Inhibition of tumor growth, angiogenesi
Get in Touch
Have questions about our products or want to discuss a custom order? Our team is ready to help you.